Press Releases

Date Title  
Toggle Summary West Pharmaceutical Services Reports Third Quarter Results; Commences Strategic Review; Announces Drug Delivery Licensing Agreements
LIONVILLE, Pa., Oct. 16 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today reported net income of $4.6 million, or $0.32 per share, compared with third quarter 1999 net income of $8.6 million, or $0.58 per share. In the Device Product Development segment, strong sales growth in
West Pharmaceutical Services Reports Third Quarter Results; Commences Strategic Review; Announces Drug Delivery Licensing Agreements
LIONVILLE, Pa., Oct. 16 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today reported net income of $4.6 million, or $0.32 per share, compared with third quarter 1999 net income of $8.6 million, or $0.58 per share. In the Device Product Development segment, strong sales growth in
Toggle Summary West Pharmaceutical Services, Inc. Announces Dividend Increase
LIONVILLE, Pa., Aug. 1 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.18 per share for the fourth quarter of 2000 payable November 1, 2000 to shareholders of record on October 18, 2000.
West Pharmaceutical Services, Inc. Announces Dividend Increase
LIONVILLE, Pa., Aug. 1 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.18 per share for the fourth quarter of 2000 payable November 1, 2000 to shareholders of record on October 18, 2000.
Toggle Summary West Pharmaceutical Services, Inc. Announces Second Quarter And Six Month Results
LIONVILLE, Pa., July 20 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the second quarter and six months ended June 30, 2000. Net sales for the second quarter were $112.7 million compared to the $124.4 million reported in the second quarter of 1999.
West Pharmaceutical Services, Inc. Announces Second Quarter And Six Month Results
LIONVILLE, Pa., July 20 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the second quarter and six months ended June 30, 2000. Net sales for the second quarter were $112.7 million compared to the $124.4 million reported in the second quarter of 1999.
Toggle Summary West Pharmaceutical Services, Inc. Comments on Second Quarter and 2000 Year - Announces Management Changes and Other Corporate Developments
LIONVILLE, Pa., June 21 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today reported that earnings for the second quarter ending June 30, 2000 and for the year are expected to be sharply lower than previously anticipated. The Company stated that the previously disclosed soft
West Pharmaceutical Services, Inc. Comments on Second Quarter and 2000 Year - Announces Management Changes and Other Corporate Developments
LIONVILLE, Pa., June 21 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today reported that earnings for the second quarter ending June 30, 2000 and for the year are expected to be sharply lower than previously anticipated. The Company stated that the previously disclosed soft
Toggle Summary West Pharmaceutical Services, Inc. Announces Dividend
LIONVILLE, Pa., June 20 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.17 per share for the third quarter of 2000 payable August 2, 2000 to shareholders of record July 19, 2000.
West Pharmaceutical Services, Inc. Announces Dividend
LIONVILLE, Pa., June 20 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.17 per share for the third quarter of 2000 payable August 2, 2000 to shareholders of record July 19, 2000.
Toggle Summary West Pharmaceutical Services, Inc. Announces First Quarter Results
LIONVILLE, Pa., April 19 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the first quarter ended March 31, 2000. Sales for the first quarter were $107.7 million compared to the $114.2 million reported in the first quarter of 1999.
West Pharmaceutical Services, Inc. Announces First Quarter Results
LIONVILLE, Pa., April 19 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the first quarter ended March 31, 2000. Sales for the first quarter were $107.7 million compared to the $114.2 million reported in the first quarter of 1999.
Toggle Summary West Pharmaceutical Services, Inc. Announces Dividend
LIONVILLE, Pa., March 27 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.17 per share for the second quarter of 2000 payable May 3, 2000 to shareholders of record April 19, 2000.
West Pharmaceutical Services, Inc. Announces Dividend
LIONVILLE, Pa., March 27 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.17 per share for the second quarter of 2000 payable May 3, 2000 to shareholders of record April 19, 2000.
Toggle Summary West Pharmaceutical Services, Inc. and Beaufor Ipsen, S.A. Enter Early-Stage Product Development Agreement
LIONVILLE, Pa., March 2 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced today that it has entered into a product development agreement with Beaufor Ipsen, S.A., a privately held French Pharmaceutical Group. The agreement involves the application of West's patented nasal
West Pharmaceutical Services, Inc. and Beaufor Ipsen, S.A. Enter Early-Stage Product Development Agreement
LIONVILLE, Pa., March 2 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced today that it has entered into a product development agreement with Beaufor Ipsen, S.A., a privately held French Pharmaceutical Group. The agreement involves the application of West's patented nasal
Toggle Summary West Pharmaceutical Services, Inc. Announces Fourth Quarter And Full Year 1999 Results
LIONVILLE, Pa., Feb. 15 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the fourth quarter and year-ended December 31, 1999. Sales for the fourth quarter were $115.4 million, compared with $114.8 million reported in the fourth quarter of 1998.
West Pharmaceutical Services, Inc. Announces Fourth Quarter And Full Year 1999 Results
LIONVILLE, Pa., Feb. 15 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the fourth quarter and year-ended December 31, 1999. Sales for the fourth quarter were $115.4 million, compared with $114.8 million reported in the fourth quarter of 1998.
Toggle Summary West Pharmaceutical Services Files IND Application For Nasal Leuprolide For The Treatment Of Endometriosis
LIONVILLE, Pa., Jan. 31 /PRNewswire/ -- West Pharmaceutical Services, Incorporated (NYSE: WST) announced today that it completed filling of an Investigational New Drug (IND) application covering a nasally administered formulation of leuprolide for the treatment of endometriosis and other selected
West Pharmaceutical Services Files IND Application For Nasal Leuprolide For The Treatment Of Endometriosis
LIONVILLE, Pa., Jan. 31 /PRNewswire/ -- West Pharmaceutical Services, Incorporated (NYSE: WST) announced today that it completed filling of an Investigational New Drug (IND) application covering a nasally administered formulation of leuprolide for the treatment of endometriosis and other selected
Toggle Summary West Pharmaceutical Services to Commence Phase I Clinical Trials for Nasal Morphine for Pain
LIONVILLE, Pa., Jan. 18 /PRNewswire/ -- West Pharmaceutical Services, Incorporated (NYSE: WST) announced today that its December 1999 IND (Investigational New Drug) application for a nasally administered formulation of morphine has now passed the FDA 30 day comment period, clearing the way for
West Pharmaceutical Services to Commence Phase I Clinical Trials for Nasal Morphine for Pain
LIONVILLE, Pa., Jan. 18 /PRNewswire/ -- West Pharmaceutical Services, Incorporated (NYSE: WST) announced today that its December 1999 IND (Investigational New Drug) application for a nasally administered formulation of morphine has now passed the FDA 30 day comment period, clearing the way for